頁籤選單縮合
題 名 | A Comparison of Clinical Use of Fluticasone Propionate and Beclomethasone Dipropionate in Pediatric Asthma=Fluticasone Propionate與Beclomethasone Dipropionate在兒童氣喘臨床使用之比較 |
---|---|
作 者 | 農寶仁; 黃永豐; 謝凱生; 黃原逸; 黃群峰; 莊上林; 劉家嘉; | 書刊名 | The Kaohsiung Journal of Medical Sciences |
卷 期 | 17:6 2001.06[民90.06] |
頁 次 | 頁302-311 |
分類號 | 418.263 |
關鍵詞 | 兒童; 氣喘; 吸入性類固醇; Asthma; Inhaled steroids; Fluticasone propionate; Beclomethasone dipropionate; |
語 文 | 英文(English) |
中文摘要 | 吸入性類固醇,在治療及預防氣喘上扮演著極重要的角色。由過去研究 顯示,Fluticasone propionate(FP)的生體可用率低及局部藥效高。然而這些數 據並非源自台灣地區,為建立本土數據,於是我們設計了為期十二週的開放、隨 機比較實驗。這些參與者是年齡約在4-14歲的中、重度氣喘患者,共77人。其 中51人在FP組,26人在beclomethasone dipropionate (BD)組。結果發現, 除了在第四週時,日間症狀分數(p=0.033,BD組較佳)之外,兩組之間的症狀 分數的改善程度並無明顯差異(p>0.05)。所有的日間或夜間症狀之p值皆小於 0.001,亦即兩組在治療後皆有明顯改善。PEF(尖峰呼氣流速)改善程度的p值 在第四週為0.003(BD組較佳),而在第八週為0.943;FEV1改善程度的p值在第 四週為0.005(BD組較佳),而在第八週為0.252;FEV1╱FVC改善程度的p值 在第四週為0.067,在第八週為0.097。不論是在四週後或八週後,TEC(total eosinophil count),IgE,ECP(eosinophil cationic protein)血清濃度的變化皆無統 計學上的差異。所有的副作用皆在預期之中,且包含cortisol值(p>0.05),皆 無統計學上的差異。 總之,台灣地區的資料顯示,100μg的FP的藥效與200μg 的BD的藥效是相等的。而且在FP組幾乎沒有什麼副作用發生,這說明了 Fluticasone propionate值得臨床使用。 |
英文摘要 | Inhaled steroids play a very important role in the prevention and treatment of asthma. Previous studies indicated that fluticasone propionate ( FP ) had low bioavailability and high local potency . However, the laboratory data in these studies were not obtained among Taiwan population. It is very important that native data should be established. Thus a 12-week research program was designed, involving 77 patients, 51 for FP group and 26 for beclomethasone dipropionate ( BD) group. The objects were victims of moderate to severe asthma and their age ranged from 4 to 14 years old. An open, comparative and randomized method was adopted. Except for the 4-week-later daytime symptom score( P=0.033, BD group was better ), no other significant differences were found between the two groups in the symptom score improvement( P>0.05 ). All the P-values for the daytime & night-time scores were lower than 0.001 , which means obvious improvement after treatment in both groups. P-value for PEF improvement was 0.003 after 4 weeks ( BD group was better ) and 0.943 after 8 weeks; for FEV1 improvement, it was 0.005 after 4 weeks( BD group was better ) and 0.252 after 8 weeks; and for FEV1/FVC improvements, it was 0.067 after 4 weeks and 0.097 after 8 weeks. There was no statistic significance in total eosinophil count ( TEC ), IgE, eosinophil cationic protein ( ECP ) serum level changes after 4 or 8 weeks. Adverse effects were all anticipated and no statistic significance showed up, either, between the two groups or in the cortisol levels ( P>0.05 ). In conclusion, native data indicated that the potency of 100μg of FP was equal to that of 200μg of BD and that few side effects were noted in FP group. It is recommended that this drug be introduced for clinical use. |
本系統中英文摘要資訊取自各篇刊載內容。